Irish medical journal 2013-01-01

Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.

L Wilson, J Sheehan, M Thorpe

Index: Ir. Med. J. 106(1) , 24-5, (2013)

Full Text: HTML

Abstract

Impulse control disorders (ICDs) are a known side effect of dopamine replacement therapy in patients with Parkinson's disease (PD). They can have devastating consequences for patients and their families.

Related Compounds

Related Articles:

Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol.

2015-01-01

[Molecules 20 , 7454-73, (2015)]

[Liver monoamine oxidase activity of the lamprey Lampetra fluviatilis. the substrate-inhibitory specificity].

2013-01-01

[Zh. Evol. Biokhim. Fiziol. 49(1) , 39-43, (2013)]

Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor.

2012-08-27

[Brain Res. 1470 , 45-51, (2012)]

Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.

2013-03-01

[J. Neural Transm. Gen. Sect. 120(3) , 435-44, (2013)]

''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?

2013-01-01

[J. Neural Transm. Gen. Sect. 120(1) , 83-9, (2013)]

More Articles...